Optimization of Treatment and Management of Schizophrenia in Europe - OPTiMiSE

niversity Medical Centre Utrecht0 个研究点目标入组 446 人开始时间: 2010年12月6日最近更新: 2020年10月13日

适应症

试验速览

暂无简介。

•i) Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder, as defined by DSM-IV on the basis of the Mini International Neuropsychiatric Interview Plus (M.I.N.I. Plus; Sheehan et al. 1998), a short diagnostic structured interview.
•ii) Age 18-40 years
•iii) Written informed consent
•iv) Mental capacity to understand and consent to the study (as determined using attached mental capacity assessment form).
•For all participants at UK site:
•iii) Adequate command of English to understand the study and complete the assessments
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•i) A time interval between the onset of positive symptoms (hallucinations and/or delusions) and study entry exceeding two years.
•ii) Prior use of antipsychotic medication for longer than an episode of two weeks in the previous year and/or 6 weeks during lifetime.
•iii) Intolerance to one of the drugs in this study.
•iv) The presence of one or more of the contraindications against any of the study drugs
•vi) Pregnancy, as determined through a pregnancy test, or lactation
•vii) Lack of mental capacity to understand and consent to the study (as determined using attached mental capacity assessment form).
•For participation in MRI scans only (if they meet this exclusion criteria, they can still participate in the rest of the study)
•i) any contraindication to imaging e.g. implanted metallic objects or electronic devices

发起方

niversity Medical Centre Utrecht